Purple biotech presents new data for its novel tri-specific t cell and nk cell engagers antibody platform, captn-3, at the eortc-nci-aacr symposium on molecular targets and cancer therapeutics

Captn-3 demonstrates s ustained tumor regression in a triple negative breast cancer in-vivo model ; a dose dependent ac tivity and a synergistic effect of the engage r arm s also seen in non-small cell lung cancer patient-derived explants

NCI Ratings Summary

NCI Quant Ranking